Cosmo Pharmaceuticals (OTCMKTS:CMOPF – Get Free Report) rose 1.7% during trading on Monday. The company traded as high as C$64.61 and last traded at C$64.00. 182 shares were traded during mid-day trading, a decline of 55% from the average session volume of 402 shares. The stock had previously closed at C$62.95.
Cosmo Pharmaceuticals Stock Performance
The stock has a fifty day simple moving average of C$68.07 and a 200-day simple moving average of C$84.44.
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V. is an international pharmaceutical company focused on developing, manufacturing and commercializing treatments for gastrointestinal and dermatological conditions. The company uses its proprietary MMX drug-delivery technology to formulate therapies designed to release active ingredients at targeted locations in the gastrointestinal tract.
Cosmo’s gastrointestinal portfolio includes products for inflammatory bowel disease and other digestive disorders, including mesalamine-based therapies and rifamycin-based treatments.
Recommended Stories
- Five stocks we like better than Cosmo Pharmaceuticals
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
